Acromegaly is a hormonal disorder, while GEP-NET is a rare type of tumor that can form in the pancreas or other parts of the gastrointestinal tract, including the stomach, small intestine, colon, rectum, and appendix.
The company said it has received final approval for lanreotide injection in dosages of 120 mg/0.5 mL, 90 mg/0.3 mL and 60 mg/0.2 mL.
It said the USFDA approval is based on an abbreviated new drug application (NDA).
Cipla's Lanreotide Injection is the AP-rated therapeutic equivalent generic version of Somatulin Depot (lanreotide) Injection.
Lanreotide injection is supplied as 120 mg/0.5 mL, 90 mg/0.3 mL, and 60 mg/0. mL single-dose, pre-filled, and ready-to-inject syringes.
According to IQVIA (IMS Health), US sales of Somatulin Depot (Lanreotide) were approximately $898 million last year i.e. till March 2024.
The company said it has received final approval for lanreotide injection in dosages of 120 mg/0.5 mL, 90 mg/0.3 mL and 60 mg/0.2 mL.
It said the USFDA approval is based on an abbreviated new drug application (NDA).
Cipla's Lanreotide Injection is the AP-rated therapeutic equivalent generic version of Somatulin Depot (lanreotide) Injection.
Lanreotide injection is supplied as 120 mg/0.5 mL, 90 mg/0.3 mL, and 60 mg/0. mL single-dose, pre-filled, and ready-to-inject syringes.
According to IQVIA (IMS Health), US sales of Somatulin Depot (Lanreotide) were approximately $898 million last year i.e. till March 2024.
